Different Immunosuppressive Treatment in iMN
Recruiting
Phase 3
Interventional Study
Idiopathic Membranous Nephropathy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 200 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The primary objective of this study is to compare the 24 month remission of different immunosuppressive therapies in the treatment of idiopathic membranous nephropathy (iMN)
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* idiopathic membranous nephropathy
* Female, must be post-menopausal, sterile or have effective contraception
* must be off steroid or mycophenolate mofetil for \>1 month and alkylating agents for or RTX\> 6 months
* Angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin…